Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month Low - Here's Why

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) reached a new 52-week low on Tuesday . The company traded as low as $30.86 and last traded at $30.73, with a volume of 240749 shares trading hands. The stock had previously closed at $31.02.

Analyst Upgrades and Downgrades

Several brokerages have commented on AMPH. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price objective for the company. Piper Sandler downgraded shares of Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and lowered their price objective for the company from $66.00 to $36.00 in a research report on Tuesday, February 4th. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $50.33.

Amphastar Pharmaceuticals Trading Down 0.1 %

The business's 50 day simple moving average is $35.62 and its two-hundred day simple moving average is $42.94. The stock has a market cap of $1.50 billion, a P/E ratio of 10.43, a PEG ratio of 2.19 and a beta of 0.81. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the sale, the director now owns 30,471 shares of the company's stock, valued at approximately $1,333,715.67. The trade was a 24.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Rong Zhou sold 7,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total transaction of $310,940.00. Following the sale, the executive vice president now directly owns 118,469 shares in the company, valued at approximately $5,262,392.98. The trade was a 5.58 % decrease in their position. The disclosure for this sale can be found here. Insiders own 27.10% of the company's stock.

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors have recently modified their holdings of AMPH. Pacer Advisors Inc. grew its stake in shares of Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after purchasing an additional 1,347,775 shares during the last quarter. Boston Trust Walden Corp bought a new stake in shares of Amphastar Pharmaceuticals in the third quarter worth $26,189,000. Boston Partners bought a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth $15,778,000. Wealthfront Advisers LLC bought a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth $9,268,000. Finally, Systematic Financial Management LP bought a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth $9,147,000. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.